SRR934916
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.36136662286465
- age_years
- 51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.338
- ALLOGRAFT_REJECTION+0.310
- ANGIOGENESIS+0.265
- INTERFERON_ALPHA_RESPONSE+0.212
- INTERFERON_GAMMA_RESPONSE+0.202
- COAGULATION+0.178
- IL6_JAK_STAT3_SIGNALING+0.178
- KRAS_SIGNALING_DN+0.148
- KRAS_SIGNALING_UP+0.137
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.132
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.463
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.422
- MITOTIC_SPINDLE-0.418
- MTORC1_SIGNALING-0.403
- MYC_TARGETS_V1-0.393
- OXIDATIVE_PHOSPHORYLATION-0.392
- ANDROGEN_RESPONSE-0.383
- MYC_TARGETS_V2-0.363
- UNFOLDED_PROTEIN_RESPONSE-0.361
- HEDGEHOG_SIGNALING-0.348
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-91-A4BC-01A-11R-A24H-07 | — | cohortA3 | 0.924 |
| 2 | SRR934910 | — | — | 0.918 |
| 3 | SRR8942994 | — | — | 0.899 |
| 4 | MNG882 | — | — | 0.894 |
| 5 | SRR1341057 | GTEX | — | 0.893 |
| 6 | SRR1355373 | GTEX | — | 0.882 |
| 7 | MNG1142 | — | — | 0.879 |
| 8 | SRR1413454 | GTEX | — | 0.878 |
| 9 | SRR1358689 | GTEX | — | 0.878 |
| 10 | EPT0776 | EPN | EPN Tumor | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.338 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.265 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.212 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.202 | Idelalisib | — uncovered |
| COAGULATION | 0.178 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.178 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.148 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.137 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.132 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.106 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| COMPLEMENT | 0.036 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.035 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.024 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.009 | Temsirolimus | — uncovered |